Skip to content

To understand the efficacy of two different types of inhaler therapy , one a dual combination therapy and other a triple combination therapy

Comparative study between the effects of triple therapy (LAMA-LABA-ICS) and LAMA-LABA in COPD patients - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/054353
Enrollment
396
Registered
2023-06-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention1: Inhaled corticosteroid: Inhaled corticosteroid in addition to long acting beta receptor and long acting muscarinic antagonist Intervention2: Triple drug inhaler: ICS,LABA,LAMA Intervent

Sponsors

Institute of Post Graduate Medical Education and Research Kolkata
Lead Sponsor
Dr Animesh Mandal
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients with equal to or more than one exacerbation needing hospital admission Patient giving consent for study

Exclusion criteria

Exclusion criteria: Patient not giving consent for the study Patients of Lung Malignancy and COPD Patients with heart failure and COPD Patient with history of Tuberculosis

Design outcomes

Primary

MeasureTime frame
Number of exacerbations in the given time frame Improvement in FEV1 & FEF25% -75% & 6 minute walk distance Number of patients who succumbed to primary disease if any in either groupsTimepoint: at base line , at 4 weeks , at 24 weeks and at end of one year or 52 weeks

Secondary

MeasureTime frame
Number of patients who had Pneumonia in either groups Any adverse effect of any drug Number of patients intolerant to Dual therapy who were shifted back to Triple therapyTimepoint: at 4 weeks , at 24 weeks , at 52 weeks

Countries

India

Contacts

Public ContactDr MD WAMIQUE IZHAR

WEST BENGAL UNIVERSITY OF HEALTH SCIENCES

haldar.ranjit@gmail.com9474441290

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026